iQ-007
Treatment-Resistant Epilepsy
Phase 1Active
Key Facts
About iQure Pharma
iQure Pharma is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, Massachusetts. The company is pioneering a novel neuroprotective strategy by developing small molecules that enhance the function of the EAAT2 glutamate transporter on astrocytes, aiming to treat a broad range of CNS disorders rooted in excitotoxicity. With its lead program, iQ-007, in a Phase 1 trial for epilepsy, the company is validating its platform and expanding into preclinical programs for neurodegeneration and pain. iQure leverages strong academic collaborations and is backed by venture capital investors.
View full company profile